| abstract |
The invention provides multivalent CD20 binding molecules and compositions thereof, such as enriched compositions comprising a large proportion of multivalent CD20 binding molecules relative to monovalent CD20 binding molecules. Certain multivalent CD20 binding molecules of the invention comprise 1) two or more CD20 binding domains and 2) one or more Shiga toxin effector polypeptide domains derived from the A subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the invention and compositions thereof are useful for selectively killing specific cell types and as therapeutic agents for the treatment of a variety of diseases, including cancer, tumors, and immune disorders. Certain multivalent CD20-binding molecules of the invention and compositions thereof are useful for the delivery of agents into CD20-expressing cells, including for intracellular labeling of CD20-expressing cells, collecting diagnostic information, and monitoring a variety of related CD20-expressing cells Treatment of diseases such as cancer, tumors and immune disorders. |